Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings.
Agomab Therapeutics NV (AGMB) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. AGMB is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of AGMB by reported 13-F value include EQT Fund Management S.a r.l., Sanofi, Redmile Group, based on the most recent SEC filings. AGMB trades on the Nasdaq exchange and files with the SEC under CIK 2020932. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AGMB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Agomab Therapeutics NV directly from SEC EDGAR.
| Institution | Shares | Value | Reported |
|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,141,992 | $66.7M | 2026-06-30 |
| Sanofi | 2,783,096 | $36.1M | 2026-06-30 |
| Redmile Group | 2,733,926 | $35.5M | 2026-06-30 |
| Cormorant Asset Management | 2,465,348 | $32.0M | 2026-06-30 |
| TCG Crossover Management | 2,053,233 | $26.7M | 2026-06-30 |
| FEDERATED HERMES | 1,618,000 | $21.0M | 2026-06-30 |
| Nantahala Capital Management | 1,568,188 | $20.4M | 2026-06-30 |
| Casdin Capital | 1,550,000 | $20.1M | 2026-06-30 |
| Andera Partners | 1,538,702 | $20.0M | 2026-06-30 |
| FMR | 1,458,677 | $18.9M | 2026-06-30 |
13F Pro Quality Score
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
Financial metrics will appear once SEC EDGAR data is ingested for this company.